Emerging treatment options for prostate cancer.

ABSTRACT:

Introduction

Prostate cancer treatment has rapidly evolved in the past few years. Androgen deprivation therapy has been the backbone of treatment for locally advanced and metastatic prostate cancer, but incremental benefits in survival have been shown by adding androgen-receptor pathway inhibitors (ARPI) across various spectrums of disease state. In addition, docetaxel chemotherapy remains the first-line chemotherapy regimen available with survival benefits shown with triplet therapy in those who are chemotherapy eligible. However, disease progression remains inevitable and novel agents such as radioligand therapy with lutetium have shown improvement in survival.

Areas covered

This review discusses the pivotal trials that led to the U.S. FDA approval of agents utilized in me

SUBMITTER: Atiq M 

PROVIDER: S-EPMC10718079 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature